Shu Kwun Lui1, Catherine R Garcia1, Xiaonan Mei1, Roberto Gedaly2. 1. Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, 800 Rose Street, Room C453, Lexington, KY, 40536-0293, USA. 2. Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, 800 Rose Street, Room C453, Lexington, KY, 40536-0293, USA. rgeda2@uky.edu.
Abstract
BACKGROUND: Hepatic artery thrombosis (HAT) is a major complication after liver transplantation that commonly requires re-transplantation. METHODS: We queried the UNOS dataset for all patients transplanted between 1995 and 2015 for HAT. RESULTS: We identified 623 patients who underwent re-transplantation for HAT with a mean age of 51.25 + 10.4 years. The mean BMI was 26.72 kg/m2, and mean MELD score was 19.62 + 9.09. There was a higher proportion of male patients, with higher prevalence of pre-transplant portal vein thrombosis (7.4 vs. 5.4%, p = 0.04), lower incidence of hepatitis C virus infection (29.5 vs. 35.8%, p = 0.002), and shorter waiting time (61 vs. 111 days, p = 0.001) in the HAT group compared to those re-transplanted for other indications. The perioperative 90-day mortality was lower in patients re-transplanted for HAT (16 vs. 20%, p = 0.02). Patients undergoing re-transplantation for HAT had 13% decreased graft survival and 13% increased long-term survival. After case-control matched analysis, graft survival and patient survival were significantly better in the HAT group. Late re-transplantation (>30 days) for HAT was linked to decreased graft and patient survival when compared to those undergoing early re-transplantation (within 30 days). CONCLUSIONS: Improved outcomes were seen in patients undergoing re-transplantation for HAT compared to patients who underwent re-transplantation for other indications. Those re-transplanted late after HAT (>30 days) were associated with worse outcomes when compared to early re-transplantation.
BACKGROUND:Hepatic artery thrombosis (HAT) is a major complication after liver transplantation that commonly requires re-transplantation. METHODS: We queried the UNOS dataset for all patients transplanted between 1995 and 2015 for HAT. RESULTS: We identified 623 patients who underwent re-transplantation for HAT with a mean age of 51.25 + 10.4 years. The mean BMI was 26.72 kg/m2, and mean MELD score was 19.62 + 9.09. There was a higher proportion of male patients, with higher prevalence of pre-transplant portal vein thrombosis (7.4 vs. 5.4%, p = 0.04), lower incidence of hepatitis C virus infection (29.5 vs. 35.8%, p = 0.002), and shorter waiting time (61 vs. 111 days, p = 0.001) in the HAT group compared to those re-transplanted for other indications. The perioperative 90-day mortality was lower in patients re-transplanted for HAT (16 vs. 20%, p = 0.02). Patients undergoing re-transplantation for HAT had 13% decreased graft survival and 13% increased long-term survival. After case-control matched analysis, graft survival and patient survival were significantly better in the HAT group. Late re-transplantation (>30 days) for HAT was linked to decreased graft and patient survival when compared to those undergoing early re-transplantation (within 30 days). CONCLUSIONS: Improved outcomes were seen in patients undergoing re-transplantation for HAT compared to patients who underwent re-transplantation for other indications. Those re-transplanted late after HAT (>30 days) were associated with worse outcomes when compared to early re-transplantation.
Authors: Michael A Silva; Periyathambi S Jambulingam; Bridget K Gunson; David Mayer; John A C Buckels; Darius F Mirza; Simon R Bramhall Journal: Liver Transpl Date: 2006-01 Impact factor: 5.799
Authors: Sabrina E Sanchez; Patrick J Javid; Oliver B Lao; André A Dick; James D Perkins; Jorge D Reyes; Simon P Horslen; Patrick J Healey; Robert Sawin Journal: J Pediatr Surg Date: 2012-06 Impact factor: 2.545
Authors: A Scarinci; M Sainz-Barriga; F Berrevoet; B van den Bossche; I Colle; A Geerts; X Rogiers; H van Vlierberghe; B de Hemptinne; R Troisi Journal: Transplant Proc Date: 2010-12 Impact factor: 1.066
Authors: S Feng; N P Goodrich; J L Bragg-Gresham; D M Dykstra; J D Punch; M A DebRoy; S M Greenstein; R M Merion Journal: Am J Transplant Date: 2006-04 Impact factor: 8.086
Authors: O Jurim; M Csete; H A Gelabert; J M Millis; K Olthoff; D Imagawa; A Shaked; S V McDiarmid; R W Busuttil Journal: J Pediatr Surg Date: 1995-01 Impact factor: 2.545
Authors: John P Duffy; Johnny C Hong; Douglas G Farmer; Rafik M Ghobrial; Hasan Yersiz; Jonathan R Hiatt; Ronald W Busuttil Journal: J Am Coll Surg Date: 2009-05 Impact factor: 6.113
Authors: Umberto Maggi; Enzo Andorno; Giorgio Rossi; Luciano De Carlis; Umberto Cillo; Fabrizio Bresadola; Vincenzo Mazzaferro; Andrea Risaliti; Paolo Bertoli; Dario Consonni; Francesco Barretta; Tullia De Feo; Mario Scalamogna Journal: PLoS One Date: 2012-10-05 Impact factor: 3.240
Authors: Bernhard Scheiner; Patrick G Northup; Anselm B Gruber; Georg Semmler; Gerda Leitner; Peter Quehenberger; Johannes Thaler; Cihan Ay; Michael Trauner; Thomas Reiberger; Ton Lisman; Mattias Mandorfer Journal: Liver Int Date: 2020-03-04 Impact factor: 5.828